Drug General Information (ID: DDIZJC80N6)
Drug Name			Peginterferon alfa-2a		Drug Info		Pegvaliase		Drug Info
Drug Type		Interferons				Protein/peptide
Therapeutic Class		Antineoplastics				Metabolic Agents

Mechanism of Peginterferon alfa-2a-Pegvaliase Interaction (Severity Level: Moderate)
Increased risk of angioedema/anaphylactoid reactions Click to Show/Hide Mechanism Graph
Drug Name		Peginterferon alfa-2a				Pegvaliase
Mechanism		Anaphylactoid reactions				Anaphylactoid reactions
Key Mechanism Factor 1
		Factor Name		Angioedema/anaphylactoid reactions
		Factor Description		Anaphylactoid reaction is a condition in which symptoms similar to an allergic reaction occur, but no immune sensitization is detected. Most commonly, the syndrome begins with skin involvement, usually pruritus, flushing, urticaria, or angioedema. Angioedema is a reaction to a trigger that causes swelling of the tissue below the inner layer of the skin, called the dermis or submucosa, and the swelling can occur on the face, throat, or around the genitals.
Mechanism Description		Increased risk of angioedema by the combination of Peginterferon alfa-2a and Pegvaliase

Recommended Action
Management		Close monitoring for anaphylaxis and other hypersensitivity reactions is recommended during concomitant use of pegvaliase with other PEGylated products (e.g., certolizumab pegol doxorubicin liposomal epoetin beta-methoxy polyethylene glycol medroxyprogesterone acetate suspension naloxegol pegademase bovine pegaptanib pegaspargase pegfilgrastim peginesatide peginterferons pegloticase pegvisomant certain formulations of recombinant antihemophilic factor and coagulation factor IX).

References
1	Product Information. Palynziq (pegvaliase). BioMarin Pharmaceutical Inc, Novato, CA.